Safety Oversight Concerns
Kim discusses the limitations of safety oversight in drug approvals, highlighting her role in a committee where she often votes against rubber-stamping drugs. She expresses concern over the reliance on post-marketing surveillance and the lack of thorough investigation into serious adverse events, particularly in light of recent vaccine discussions. Ahmad echoes these sentiments, questioning the adequacy of current monitoring practices.In this clip
From this podcast
Doc Malik
#100 - Kim Witczak Explains The Spider Web Of Big Pharma Influence
Related Questions